Is white matter involved in patients entered into typical trials of neuroprotection? - Wikidata - awgldk - TriplyDB

Is white matter involved in patients entered into typical trials of neuroprotection?

Is white matter involved in patients entered into typical trials of neuroprotection?

http://www.wikidata.org/entity/Q48706975

about

White matter injury in ischemic stroke.Effect of Cyclosporine on Lesion Growth and Infarct Size within the White and Gray Matter.Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury Tissue plasminogen activator prevents white matter damage following stroke.Demyelination as a rational therapeutic target for ischemic or traumatic brain injury.Rosiglitazone Promotes White Matter Integrity and Long-Term Functional Recovery After Focal Cerebral Ischemia.Neuroprotection and stroke: time for a compromise.The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.Aging of cerebral white matter.Axonal protection achieved by blockade of sodium/calcium exchange in a new model of ischemia in vivo Effects of Erythropoietin on Gliogenesis during Cerebral Ischemic/Reperfusion Recovery in Adult Mice.Toll-like Receptor 2: A Novel Therapeutic Target for Ischemic White Matter Injury and Oligodendrocyte Death.Soluble epoxide hydrolase inhibition Promotes White Matter Integrity and Long-Term Functional Recovery after chronic hypoperfusion in mice Implantation of Brain-Derived Extracellular Matrix Enhances Neurological Recovery after Traumatic Brain Injury.A Post-stroke Therapeutic Regimen with Omega-3 Polyunsaturated Fatty Acids that Promotes White Matter Integrity and Beneficial Microglial Responses after Cerebral Ischemia.Progesterone pharmacokinetics in the mouse: implications for potential stroke therapy.C-Phycocyanin and Phycocyanobilin as Remyelination Therapies for Enhancing Recovery in Multiple Sclerosis and Ischemic Stroke: A Preclinical Perspective.Human In Vitro Models of Ischaemic Stroke: a Test Bed for Translation Neuroprotection: where to now?

P2860

Q31080285-D822DB6D-F018-4D14-8D75-707422C2BAE4 Q33606943-40F84749-EAEE-44AC-9ADE-CACB6C18001F Q34727045-AC0226C1-1952-4950-A4B5-71B0EC5BA231 Q35213585-B4B5FB38-1B75-4442-B81D-5AF0BD76EB55 Q36090107-DC4F40A6-3DB4-439E-AC78-FA721287A4B6 Q36191138-ACB80796-8467-4ACC-BE67-7BD51926B94E Q36922560-2BE61BBB-386B-42F8-A560-B4BD9457455A Q38522653-FF9FB6AF-1C17-4107-AD3E-DCDE2D2487F2 Q39014387-07A6D2B4-5473-4D3D-9D35-8F694B7A7A29 Q40819221-5C110932-3D6B-45D2-B6EA-5802D4FA8FC3 Q41108732-6A77A25F-AB6D-47E8-BB27-3BEBE384667C Q41128526-F948C9A1-3AC4-4867-9DCC-EA918834697F Q41354081-8462E657-5E27-4CB3-B449-125B9F9B7A10 Q42184310-7EE354BB-049D-40C9-89E1-0A8F2FAC9C64 Q48039676-82F2F2E3-5ABB-4855-A40B-2FF847C8DA3B Q48339775-6D09C644-CAD7-464E-A872-7D5B4A864E1A Q49272997-A509EC77-2067-4824-8008-8E2A71007971 Q57563997-5F71E5C9-29A0-4ACD-B870-0FBE86B74505 Q57564070-7CB1A297-49CC-4C26-A658-5E7B6EE79AF0

P2860

Is white matter involved in patients entered into typical trials of neuroprotection?

http://www.wikidata.org/entity/Q48706975

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Is white matter involved in patients entered into typical trials of neuroprotection?

@en

Is white matter involved in patients entered into typical trials of neuroprotection?

@nl

type

label

Is white matter involved in patients entered into typical trials of neuroprotection?

@en

Is white matter involved in patients entered into typical trials of neuroprotection?

@nl

prefLabel

Is white matter involved in patients entered into typical trials of neuroprotection?

@en

Is white matter involved in patients entered into typical trials of neuroprotection?

@nl

P1433

Q48706975-B0EA74B8-3CEA-472E-B814-97623EEA0C70

P1476

Q48706975-FA81DAEA-5A8B-425B-97A7-09C4D3DAA219

P2093

Q48706975-533B2240-F08E-4B30-BBD0-6DC8AD945F18

Q48706975-A1BF18CE-ED57-42F3-8A8D-024547ED1212

Q48706975-BB93D178-A229-4D1E-8CEF-CB2B5392DA91

Q48706975-F168ABED-F502-439F-9F96-78F795D299F9

Q48706975-F1DB414D-20E4-4F16-AA2D-22C21BA31F88

P304

Q48706975-7FE507CC-E9F8-483C-A20F-68881E72BBC4

P31

Q48706975-EB7EC10C-C6E1-4129-92AA-E476453C8F17

P356

Q48706975-D14716A6-DA92-42E2-A87D-66B2432FFE5F

P407

Q48706975-3FE8CCAB-7014-4544-9301-738F4FBA7EC9

P433

Q48706975-655027EC-0E79-4932-8DED-F8C0AEAFB297

P478

Q48706975-2E157C4E-371E-4F63-8CE2-D2193939B98E

P50

Q48706975-24CD7B70-1128-4B99-AFF0-0A66687C1D42

Q48706975-51A9F616-96C2-4BB4-A641-D7EA6A54931C

Q48706975-52D47A85-5F44-4A80-83B8-51AD6B0CE7A9

P577

Q48706975-49B573EC-5CC8-4C74-A6C2-9712098E848F

P698

Q48706975-AA444025-F5EE-4726-9F82-1F9D71E9CA9D

P356

01.STR.0000189748.52500.A7

P1433

P1476

Is white matter involved in patients entered into typical trials of neuroprotection?

@en

P2093

Dennis Young

http://www.w3.org/2001/XMLSchema#string

Indra Indra

http://www.w3.org/2001/XMLSchema#string

Peter M Wright

http://www.w3.org/2001/XMLSchema#string

Romesh Markus

http://www.w3.org/2001/XMLSchema#string

Thanh G Phan

http://www.w3.org/2001/XMLSchema#string

P304

2742-2744

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.STR.0000189748.52500.A7

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Geoffrey A. Donnan

David C. Reutens

P577

2005-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16269640

http://www.w3.org/2001/XMLSchema#string